Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Abramson · SciRah

Researcher profile · Semantic Scholar

J. Abramson

Share profile

J. Abramson — researcher profile on SciRah

h-index: 59
Works: 311
Citations: 13K

Most-cited papers

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
M. Kamdar, S. Solomon, J. Arnason, P. Johnston +17 more
2022The Lancet478 citations Open access
Semantic Scholar
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
J. Abramson, S. Solomon, J. Arnason, P. Johnston +14 more
2022Blood378 citations Open access
Semantic Scholar
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.
C. Jacobson, B. Hunter, R. Redd, S. Rodig +23 more
2020Journal of Clinical Oncology295 citations Open access
Semantic Scholar
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
S. Ansell, J. Radford, J. Connors, M. Długosz-Danecka +17 more
2022New England Journal of Medicine274 citations Open access
Semantic Scholar
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
T. Neilan, T. Quinaglia, Takeshi Onoue, Syed S Mahmood +31 more
2023Journal of the American Medical Association (JAMA)193 citations Open access
Semantic Scholar
Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA‐1, and TRANSCEND trials
J. Westin, M. Kersten, G. Salles, J. Abramson +3 more
2021American journal of hematology/oncology178 citations Open access
Semantic Scholar
Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines.
Carlos A. Gongora, Z. Drobni, Thiago Quinaglia Araujo Costa Silva, A. Zafar +15 more
2022JACC. Heart failure133 citations Open access
Semantic Scholar
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
A. Zelenetz, L. Gordon, Julie E. Chang, B. Christian +33 more
2021The Journal of the National Comprehensive Cancer Network132 citations Open access
Semantic Scholar
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
W. Wierda, Jennifer R. Brown, J. Abramson, Farrukh T. Awan +30 more
2022The Journal of the National Comprehensive Cancer Network86 citations Open access
Semantic Scholar
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
J. Soumerai, A. Mato, A. Dogan, V. Seshan +42 more
2021The Lancet Haematology85 citations Open access
Semantic Scholar
Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma
N. Thomas, K. Dreval, D. Gerhard, L. Hilton +64 more
2022Blood74 citations Open access
Semantic Scholar
Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma
K. Miller, P. C. Johnson, J. Abramson, J. Soumerai +7 more
2022Blood Cancer Journal60 citations Open access
Semantic Scholar
Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)
J. Abramson, M. Palomba, L. Gordon, M. Lunning +13 more
2021Blood52 citations Open access
Semantic Scholar
Spatial Signatures Identify Immune Escape via PD-1 as a Defining Feature of T-cell/Histiocyte-rich Large B-cell Lymphoma.
G. Griffin, J. Weirather, M. Roemer, Mikel Lipschitz +27 more
2020Blood49 citations Open access
Semantic Scholar
Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy
J. Woyach, A. Ruppert, N. Heerema, Wei-Qiang Zhao +23 more
2021Blood48 citations Open access
Semantic Scholar
ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing
L. Lekakis, F. Locke, M. Tees, S. Neelapu +13 more
2021Blood40 citations Open access
Semantic Scholar
A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
K. Blum, J. Supko, M. Maris, I. Flinn +9 more
2022Cancer Research Communications33 citations Open access
Semantic Scholar
Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial.
J. Abramson, T. Siddiqi, Jacob Garcia, C. Dehner +7 more
2021Blood Advances32 citations Open access
Semantic Scholar
Assessing the Role of Radiotherapy in Patients with Refractory or Relapsed High-Grade B-Cell Lymphomas Treated with CAR T-Cell Therapy.
H. Ababneh, J. Abramson, P. Johnson, C. Patel
2022Radiotherapy and Oncology31 citations
Semantic Scholar
Neurotoxicity and management of primary and secondary CNS lymphoma after adoptive immunotherapy with CD19-directed CAR T-cells.
P. Karschnia, I. Arrillaga-Romany, A. Eichler, D. Forst +23 more
2023Neuro-Oncology30 citations
Semantic Scholar
Engineered T Cells: CAR T Cell Therapy and Beyond
P. C. Johnson, J. Abramson
2022Current Oncology Reports29 citations
Semantic Scholar
Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation.
D. Sermer, P. Elavalakanar, J. Abramson, M. Palomba +2 more
2022Blood reviews26 citations Open access
Semantic Scholar
Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma
J. Abramson, Elizabeth Bengston, R. Redd, J. Barnes +12 more
2022Blood Advances24 citations Open access
Semantic Scholar
Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network
Dora Dias-Santagata, R. Heist, Adam Z. Bard, Annacarolina F. L. Da Silva +46 more
2022The Oncologist24 citations Open access
Semantic Scholar
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL
J. Abramson, P. Johnston, M. Kamdar, S. Ibrahimi +13 more
2022Blood Advances24 citations Open access
Semantic Scholar
Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701
J. Abramson, A. Ruppert, S. Giri, Ann Hudson +9 more
2021Blood24 citations Open access
Semantic Scholar
ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.
J. Abramson, N. Ghosh, Sonali M. Smith
2020American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting23 citations
Semantic Scholar
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.
S. Rutherford, J. Abramson, N. Bartlett, S. Barta +8 more
2021The Lancet Haematology21 citations
Semantic Scholar
First-in-human data of ALLO-501A, an allogeneic chimeric antigen receptor (CAR) T-cell therapy and ALLO-647 in relapsed/refractory large B-cell lymphoma (R/R LBCL): ALPHA2 study.
F. Locke, Shahbaz Malik, M. Tees, S. Neelapu +7 more
202121 citations
Semantic Scholar
Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma.
J. Soumerai, A. Rosenthal, Shannon K Harkins, Jessica Duffy +21 more
2022Blood19 citations Open access
Semantic Scholar
Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study
J. Haydu, Jenny S. Maron, R. Redd, Kathleen M. E. Gallagher +26 more
2022Blood Advances19 citations Open access
Semantic Scholar
EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential
Yong Li, Zijun Y. Xu-Monette, J. Abramson, A. Sohani +21 more
2022Blood Advances18 citations Open access
Semantic Scholar
Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy
H. Ababneh, A. Ng, M. Frigault, J. Abramson +3 more
2023Haematologica17 citations Open access
Semantic Scholar
TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
F. Morschhauser, S. Dahiya, M. Palomba, A. García-Sancho +23 more
2023Hematological Oncology17 citations Open access
Semantic Scholar
Positron Emission Tomography–Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance)
A. LaCasce, T. Dockter, A. Ruppert, L. Kostakoglu +9 more
2022Journal of Clinical Oncology17 citations
Semantic Scholar
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐1 study
M. Hutchings, J. Radford, S. Ansell, Á. Illés +16 more
2020Hematological Oncology17 citations Open access
Semantic Scholar
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
A. Ruppert, Allison M. Booth, W. Ding, N. Bartlett +16 more
2021Leukemia16 citations Open access
Semantic Scholar
Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel
N. Olson, S. Ragan, David J. Reiss, J. Thorpe +5 more
2023Molecular Cancer Therapeutics15 citations Open access
Semantic Scholar
Preliminary Safety and Efficacy from a Multicenter, Investigator-Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen)
Anita Kumar, J. Soumerai, J. Abramson, C. Batlevi +20 more
2021Blood13 citations Open access
Semantic Scholar
First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1.
S. Ansell, J. Connors, J. Radford, W. Kim +16 more
2022Journal of Clinical Oncology10 citations
Semantic Scholar
CAR T-Cell therapies in lymphoma: current landscape, ongoing investigations, and future directions
J. E. Haydu, J. Abramson
2021Journal of Cancer Metastasis and Treatment10 citations Open access
Semantic Scholar
Phase I study of the Bcl-2 inhibitor venetoclax with DA-EPOCH-R as initial therapy for aggressive B-cell lymphomas.
S. Rutherford, J. Abramson, N. Bartlett, Stefan K. Barta +8 more
202010 citations
Semantic Scholar
Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study
Zola Musimar, Mtonga Mpetani, J. Abramson, B. Chabner +1 more
2023The Oncologist9 citations Open access
Semantic Scholar
Post-CAR relapse in DLBCL: a fork in the road.
J. Abramson
2022Blood9 citations Open access
Semantic Scholar
LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN R/R MCL: PRIMARY ANALYSIS RESULTS FROM THE MCL COHORT OF THE SINGLE‐ARM, MULTICENTER, SEAMLESS DESIGN TRANSCEND NHL 001 STUDY
M. Wang, T. Siddiqi, L. Gordon, M. Kamdar +15 more
2023Hematological Oncology8 citations Open access
Semantic Scholar
CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL).
A. LaCasce, T. Dockter, A. Ruppert, L. Kostakoglu +9 more
20218 citations
Semantic Scholar
Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)
Hun Lee, J. Abramson, N. Bartlett, J. Burke +16 more
2022Blood7 citations Open access
Semantic Scholar
Current Treatment of Burkitt Lymphoma and High-Grade B-Cell Lymphomas.
P. C. Johnson, J. Abramson
2022Oncology7 citations Open access
Semantic Scholar
Results of a completed phase I study of LAM-002 (apilimod dimesylate), a first-in-class phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) inhibitor, administered as monotherapy or with rituximab or atezolizumab to patients with previously treated follicular lymphoma or other B-cell cancers.
Catherine S. Magid Diefenbach, J. Cohen, W. Harb, S. Ansell +16 more
20207 citations
Semantic Scholar
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
C. Ryan, D. Brander, P. Barr, S. Tyekucheva +14 more
2023Leukemia6 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Bartlett×12
Invite
N. Bartlett — researcher profile on SciRah
A. LaCasce×8
Invite
A. LaCasce — researcher profile on SciRah
J. Arnason×6
Invite
J. Arnason — researcher profile on SciRah
Ephraim P. Hochberg×6
Invite
Ephraim P. Hochberg — researcher profile on SciRah

×5

Invite

M. Kamdar — researcher profile on SciRah

Invite

S. Solomon — researcher profile on SciRah

Invite

C. Jacobson — researcher profile on SciRah

Invite

J. Barnes — researcher profile on SciRah

Invite

E. Hsi — researcher profile on SciRah

Invite

M. Palomba — researcher profile on SciRah

Invite

A. Ruppert — researcher profile on SciRah

Invite

J. Leonard — researcher profile on SciRah